benfluorex has been researched along with Obesity in 20 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Excerpt | Relevance | Reference |
---|---|---|
"3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 9.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
"To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 9.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
"3 ng/mL, means +/- SE), the clinical and metabolic effects of benfluorex (B), a lipid-lowering drug able to improve insulin sensitivity." | 5.08 | Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. ( Camisasca, R; Cassisa, C; Pacchioni, M; Piatti, PM; Pontiroli, AE; Pozza, G, 1996) |
"To evaluate the change in lipids and insulin sensitivity in 10 obese type II diabetic patients after treatment with benfluorex or placebo for 2 wk." | 5.07 | Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
" Benfluorex treatment improves insulin sensitivity and has antihyperglycemic and hypolipidemic effects in human beings and in experimental animals." | 4.78 | [Mode of action of benfluorex. Recent data]. ( Brindley, DN, 1992) |
" Body weight, insulin, and leptin were decreased (p < 0." | 3.76 | MR molecular imaging of aortic angiogenesis. ( Cai, K; Caruthers, SD; Huang, W; Lanza, GM; Wickline, SA; Williams, TA; Winter, PM; Zhang, H, 2010) |
" Benfluorex has both anorectic and metabolic effects that lower body weight and improve insulin sensitivity in obesity and type 2 diabetes." | 3.69 | Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. ( Amy, RM; Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC; Wood, GO, 1997) |
"Rats of the JCR:LA-corpulent strain were treated with benfluorex daily at a dose of 25 mg/kg body weight." | 3.68 | Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex. ( al-Sieni, AI; Brindley, DN; Hales, P; Russell, JC, 1991) |
"Benfluorex + insulin is a valid alternative for obese patients who remain poorly controlled despite insulin or who require high doses of insulin." | 2.69 | Added benfluorex in obese insulin-requiring type 2 diabetes. ( Bauduceau, B; Brun, JM; Guillon-Metz, F; Leutenegger, M; Martin, C; Nicolino-Peltier, C; Richard, JL; Vannereau, D, 1998) |
"Benfluorex hydrochloride has known lipid- and glucose-lowering effects." | 2.67 | Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients. ( Bianchi, R; Bongers, V; Bravenboer, B; Erkelens, DW, 1993) |
"Benfluorex was well tolerated by all patients and no adverse event was reported." | 2.66 | Effects of benfluorex in obese patients with metabolic disorders. ( di Martino, G; Federico, P; Jacono, G; Mattera, E, 1989) |
"Benfluorex treatment and pair feeding decreased serum triacylglycerol concentrations by about 50%; there was a preferential loss of triacylglycerols containing longer chain fatty acids in the males, whereas this selectivity was not seen in the females." | 1.29 | Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. ( Brindley, DN; Dolphin, PJ; Graham, SE; Russell, JC, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (10.00) | 18.7374 |
1990's | 11 (55.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (35.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Tribouilloy, C | 3 |
Maréchaux, S | 2 |
Jobic, Y | 2 |
Jeu, A | 1 |
Ederhy, S | 1 |
Donal, E | 1 |
Réant, P | 1 |
Arnalsteen, E | 1 |
Boulanger, J | 1 |
Garban, T | 1 |
Ennezat, PV | 2 |
Andréjak, M | 2 |
Rusinaru, D | 2 |
Malergue, MC | 1 |
Bruneval, P | 1 |
Czitrom, D | 1 |
Henon, P | 2 |
Tribouilloy, L | 1 |
Leleu, F | 1 |
Sevestre, H | 1 |
Peltier, M | 1 |
Caus, T | 1 |
Cai, K | 1 |
Caruthers, SD | 1 |
Huang, W | 1 |
Williams, TA | 1 |
Zhang, H | 1 |
Wickline, SA | 1 |
Lanza, GM | 1 |
Winter, PM | 1 |
Le Ven, F | 1 |
Habib, G | 1 |
Gueffet, JP | 1 |
Eicher, JC | 1 |
Blanchard-Lemoine, B | 1 |
Rousseau, J | 1 |
Etienne, Y | 1 |
Nau, JY | 2 |
Bianchi, R | 2 |
Bongers, V | 2 |
Bravenboer, B | 2 |
Erkelens, DW | 2 |
Brindley, DN | 5 |
Pontiroli, AE | 1 |
Pacchioni, M | 1 |
Piatti, PM | 1 |
Cassisa, C | 1 |
Camisasca, R | 1 |
Pozza, G | 1 |
Russell, JC | 3 |
Graham, SE | 2 |
Dolphin, PJ | 2 |
Amy, RM | 1 |
Wood, GO | 1 |
Leutenegger, M | 1 |
Bauduceau, B | 1 |
Brun, JM | 2 |
Guillon-Metz, F | 1 |
Martin, C | 1 |
Nicolino-Peltier, C | 1 |
Richard, JL | 1 |
Vannereau, D | 1 |
Chaine, B | 1 |
Morand, JJ | 1 |
Folchetti, G | 1 |
Hesse, S | 1 |
Jean-Pastor, MJ | 1 |
Bonerandi, JJ | 1 |
Asmal, AC | 1 |
Leary, WP | 1 |
Deppe, W | 1 |
Lockett, CJ | 1 |
Hales, P | 1 |
al-Sieni, AI | 1 |
di Martino, G | 1 |
Federico, P | 1 |
Mattera, E | 1 |
Jacono, G | 1 |
2 reviews available for benfluorex and Obesity
Article | Year |
---|---|
Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fenfluramine; Humans; Hyperlipidemias; Hypogl | 1993 |
[Mode of action of benfluorex. Recent data].
Topics: Animals; Arteriosclerosis; Diabetes Mellitus, Type 2; Drug Interactions; Fatty Acids; Female; Fenflu | 1992 |
6 trials available for benfluorex and Obesity
Article | Year |
---|---|
Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; | 1993 |
Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Appetite Depressants; Blood Glucose; C-Peptide; Cholesterol; | 1993 |
Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
Topics: 3-Hydroxybutyric Acid; Appetite Depressants; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mel | 1996 |
Added benfluorex in obese insulin-requiring type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus | 1998 |
[Antidiabetic efficacy of benfluorex. Clinical data].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fenfluramine; Humans; Hypolipidemic A | 1992 |
Effects of benfluorex in obese patients with metabolic disorders.
Topics: Blood Glucose; Female; Fenfluramine; Hormones; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic | 1989 |
12 other studies available for benfluorex and Obesity
Article | Year |
---|---|
Frequency of drug-induced valvular heart disease in patients previously exposd to benfluorex: a multicentre prospective study.
Topics: Analysis of Variance; Aortic Valve Insufficiency; Appetite Depressants; Case-Control Studies; Diabet | 2013 |
Fatal dynamic mitral regurgitation as a presentation of benfluorex-Induced valvular heart toxicity.
Topics: Aged; Appetite Depressants; Autopsy; Echocardiography; Fatal Outcome; Fenfluramine; Heart Valve Pros | 2015 |
Restrictive organic mitral regurgitation associated with benfluorex therapy.
Topics: Aged; Appetite Depressants; Body Mass Index; Cardiomyopathy, Restrictive; Diabetes Mellitus; Drug Th | 2010 |
MR molecular imaging of aortic angiogenesis.
Topics: Animals; Aorta; Appetite Depressants; Atherosclerosis; Body Weight; Cholesterol; Disease Models, Ani | 2010 |
Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry.
Topics: Appetite Depressants; Body Mass Index; Comorbidity; Dose-Response Relationship, Drug; Echocardiograp | 2011 |
[What were the indications for the Mediator in 1979?].
Topics: Anxiety; Appetite Depressants; Diabetes Mellitus, Type 2; Fenfluramine; France; Heart Valve Diseases | 2011 |
[The French are wary of their drugs].
Topics: Appetite Depressants; Body Mass Index; Cause of Death; Drugs, Generic; Fenfluramine; France; Heart V | 2011 |
Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat.
Topics: Animals; Body Weight; Disease Models, Animal; Eating; Female; Fenfluramine; Hypolipidemic Agents; In | 1996 |
Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats.
Topics: Animals; Arteriosclerosis; Fenfluramine; Hypolipidemic Agents; Insulin Resistance; Male; Obesity; Ra | 1997 |
[Urticaria and anaphylactic shock from benfluorex. Two case reports].
Topics: Adverse Drug Reaction Reporting Systems; Anaphylaxis; Appetite Depressants; Female; Fenfluramine; Fr | 1998 |
The effects of benfluramate on carbohydrate metabolism in obesity.
Topics: Adult; Blood Glucose; Body Weight; Carbohydrate Metabolism; Female; Fenfluramine; Humans; Kinetics; | 1977 |
Decreased serum lipids, serum insulin and triacylglycerol synthesis in adipose tissue of JCR:LA-corpulent rats treated with benfluorex.
Topics: Adipose Tissue; Animals; Body Weight; Feeding Behavior; Female; Fenfluramine; Glucose; Hormones; Hyp | 1991 |